Comera Life Sciences (CMRA) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock CMRA vs. TRVN, ARDS, STAB, NAVB, GNCAQ, GNCA, EVLO, AMPE, CALA, and EFTRShould you be buying Comera Life Sciences stock or one of its competitors? The main competitors of Comera Life Sciences include Trevena (TRVN), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Evelo Biosciences (EVLO), Ampio Pharmaceuticals (AMPE), Calithera Biosciences (CALA), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry. Comera Life Sciences vs. Its Competitors Trevena Aridis Pharmaceuticals Statera Biopharma Navidea Biopharmaceuticals Genocea Biosciences Genocea Biosciences Evelo Biosciences Ampio Pharmaceuticals Calithera Biosciences eFFECTOR Therapeutics Comera Life Sciences (NASDAQ:CMRA) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership. Does the media prefer CMRA or TRVN? In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score. Company Overall Sentiment Comera Life Sciences Neutral Trevena Neutral Do institutionals & insiders hold more shares of CMRA or TRVN? 13.6% of Trevena shares are owned by institutional investors. 8.9% of Comera Life Sciences shares are owned by insiders. Comparatively, 2.7% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts rate CMRA or TRVN? Trevena has a consensus target price of $5.00, suggesting a potential upside of 41,566.67%. Given Trevena's stronger consensus rating and higher probable upside, analysts clearly believe Trevena is more favorable than Comera Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Comera Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Trevena 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is CMRA or TRVN more profitable? Company Net Margins Return on Equity Return on Assets Comera Life SciencesN/A N/A N/A Trevena N/A N/A -119.55% Which has more volatility and risk, CMRA or TRVN? Comera Life Sciences has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, Trevena has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Which has higher valuation & earnings, CMRA or TRVN? Comera Life Sciences has higher revenue and earnings than Trevena. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioComera Life Sciences$1.00M0.00-$18MN/AN/ATrevena$443K0.03-$40.29M-$47.040.00 SummaryComera Life Sciences beats Trevena on 5 of the 8 factors compared between the two stocks. Get Comera Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart CMRA vs. The Competition Export to ExcelMetricComera Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3K$1.03B$6.13B$10.55BDividend YieldN/A4.84%5.72%4.83%P/E RatioN/A1.3285.7827.06Price / SalesN/A29.96612.92132.30Price / CashN/A17.6325.8230.35Price / BookN/A8.0712.226.58Net Income-$18M-$7.36M$3.33B$276.84M Comera Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMRAComera Life SciencesN/AN/AN/AN/A$3K$1.00M0.002TRVNTrevena1.4481 of 5 stars$0.01flat$5.00+41,566.7%-99.4%$12K$443K0.0040ARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$11KN/A0.0030Gap DownSTABStatera BiopharmaN/A$0.00+100.0%N/AN/A$11KN/A0.0020Gap DownNAVBNavidea BiopharmaceuticalsN/AN/AN/AN/A$10K$8.13K0.0010GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070EVLOEvelo BiosciencesN/A$0.00-60.0%N/A-33.3%$4KN/A0.00120AMPEAmpio PharmaceuticalsN/A$0.00flatN/A+22.7%$3KN/A0.0020CALACalithera BiosciencesN/A$0.00+100.0%N/AN/A$1KN/A0.0060EFTReFFECTOR Therapeutics0.1491 of 5 stars$0.00flatN/A-83.3%$1KN/A0.0010Upcoming Earnings Related Companies and Tools Related Companies TRVN Competitors ARDS Competitors STAB Competitors NAVB Competitors GNCAQ Competitors GNCA Competitors EVLO Competitors AMPE Competitors CALA Competitors EFTR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMRA) was last updated on 10/20/2025 by MarketBeat.com Staff From Our Partners$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBankrupt to billionaire after retirement?Expert Reveals: The #1 Retirement Play for 2025 "We're Entering the Greatest Energy Bull Market Since the I...Brownstone Research | SponsoredTrump Issues Surprise Emergency OrderIs This Stock the 'Next Nvidia'? Billionaire Warren Buffett has been loading up on millions of shares of th...Altimetry | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Comera Life Sciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Comera Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
